APA

Gane E. J., Kowdley K. V., Pound D., Stedman C. A. M., Davis M., Etzkorn K., Gordon S. C., Bernstein D., Everson G., Rodriguez-Torres M., Tsai N., Khalid O., Yang J. C., Lu S., Dvory-Sobol H., Stamm L. M., Brainard D. M., McHutchison J. G., Tong M., Chung R. T., Beavers K., Poulos J. E., Kwo P. Y. & Nguyen M. H. (20170531). Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial. : Gastroenterology.

Chicago

Gane Edward J, Kowdley Kris V, Pound David, Stedman Catherine A M, Davis Mitchell, Etzkorn Kyle, Gordon Stuart C, Bernstein David, Everson Gregory, Rodriguez-Torres Maribel, Tsai Naoky, Khalid Omer, Yang Jenny C, Lu Sophia, Dvory-Sobol Hadas, Stamm Luisa M, Brainard Diana M, McHutchison John G, Tong Myron, Chung Raymond T, Beavers Kimberly, Poulos John E, Kwo Paul Y and Nguyen Mindie H. 20170531. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial. : Gastroenterology.

Harvard

Gane E. J., Kowdley K. V., Pound D., Stedman C. A. M., Davis M., Etzkorn K., Gordon S. C., Bernstein D., Everson G., Rodriguez-Torres M., Tsai N., Khalid O., Yang J. C., Lu S., Dvory-Sobol H., Stamm L. M., Brainard D. M., McHutchison J. G., Tong M., Chung R. T., Beavers K., Poulos J. E., Kwo P. Y. and Nguyen M. H. (20170531). Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial. : Gastroenterology.

MLA

Gane Edward J, Kowdley Kris V, Pound David, Stedman Catherine A M, Davis Mitchell, Etzkorn Kyle, Gordon Stuart C, Bernstein David, Everson Gregory, Rodriguez-Torres Maribel, Tsai Naoky, Khalid Omer, Yang Jenny C, Lu Sophia, Dvory-Sobol Hadas, Stamm Luisa M, Brainard Diana M, McHutchison John G, Tong Myron, Chung Raymond T, Beavers Kimberly, Poulos John E, Kwo Paul Y and Nguyen Mindie H. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial. : Gastroenterology. 20170531.